Prospective, Single-Center, Phase II Study to Standardize the Mitotane Dosing Regimen in Combination with Platinum-Based Chemotherapy in the First-Line Treatment for Adrenocortical Cancer

Жуликов, Я.А.; Артамонова, Е.В.; Коваленко, Е.И.; Бохян, В.Ю.; Рослякова, А.А.; Евдокимова, Е.В.; Гаджиева, К.Р.; Мартынова, О.А.; Колобанова, Е.С.; Стилиди, И.С.

Авторы: Жуликов Ярослав Андреевич, Артамонова Елена Владимировна, Коваленко Елена Игоревна, Бохян Ваган Юрикович, Рослякова Анна Александровна, Евдокимова Екатерина Вадимовна, Гаджиева Кизлер Рифкатовна, Мартынова Ольга Андреевна, Колобанова Евгения Сергеевна, Стилиди Иван Сократович
Журнал: Вопросы онкологии
Том: 72
Номер: 1
Год издания: 2026
DOI: 10.37469/0507-3758-2026-72-1-of-2404
Аннотация: Introduction. The combination of EDP (etoposide, doxo-rubicin, cisplatin) chemotherapy with mitotane represents the standard first-line therapy for adrenocortical carcinoma (ACC). Achieving therapeutic serum concentrations of mitotane has been associated with improved progression-free survival (PFS) and overall survival (OS) in several studies. However, mitotane dosing in most prior research has followed institution-specific protocols, underscoring the need for a validated and standard-ized dosing regimen.Materials and Methods. A single-center, prospective, phase II study was conducted using a Simon’s two-stage de-sign. Eligible patients had locally advanced or metastatic ACC, ECOG performance status 0−1, and were naïve to mitotane. The primary endpoint was the rate of achieving therapeutic mitotane concentrations (14–20 μg/mL). The study aimed to increase this rate from a historical 50 to 70 % (β = 0.2; α = 0.05).Secondary endpoints included objective response rate (ORR), disease control (DC) ≥ 6 months, PFS, OS, and safety. Mitotane was initiated at 2 g/day, with dose escalation by 0.5 g every 3−5 days to a maximum of 4 g/day, followed by titration based on serum drug levels. All patients concur-rently received standard platinum-based chemotherapy (EDP or EP/EC).Results. Forty-seven patients were enrolled (27 male, 57.4 %). All received platinum-based chemotherapy, 45 (95.8 %) with EDP, 2 with EP/EC. After a median follow-up of 12.4 months, therapeutic mitotane concentration was achieved in 72.3 % of patients (n = 34), with a median time to achieve-ment of 4.3 months (95 % CI 3.3–5.3). The ORR was 29.7 %, and DC ≥ 6 months was 63.8 %. Median PFS was 8.4 months (95 % CI 4.2–12.6), and median OS was 24.6 months (95 % CI 9.9–44.6). The safety profile was consistent with prior reports.Conclusion. The investigated mitotane dosing regimen fa-cilitates rapid and safe attainment of therapeutic drug levels in the majority of patients and can be recommended for routine clinical practice.Keywords: adrenocortical cancer; mitotane; EDPFor Сitation: Yaroslav A. Zhulikov, Elena V. Artamonova, Elena I. Kovalenko, Vagan Yu. Bokhian, Anna A. Roslyakova, Ekaterina V. Evdokimova, Kizler R. Gadzhieva, Olga A. Mar-tynova, Evgenia S. Kolobanova, Ivan S. Stilidi. Prospective, single-center, phase II study to standardize the mitotane dos-ing regimen in combination with platinum-based chemotherapy in the first-line treatment for adrenocortical cancer.
Добавил в систему: Жуликов Ярослав Андреевич

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ПсковГУ
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИСТИНА ПсковГУ

Prospective, Single-Center, Phase II Study to Standardize the Mitotane Dosing Regimen in Combination with Platinum-Based Chemotherapy in the First-Line Treatment for Adrenocortical Cancerстатья Исследовательская статья

Прикрепленные файлы